ArticleArchives of osteoporosis2026
Bone microarchitectural degradation in hypertensive patients: a population-based study.
Article in Archives of osteoporosis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension is associated with increased fracture risk. However, evidence on its association with BMD is conflicting. Here, we demonstrate that hypertensive patients have lower trabecular bone scores compared to normotensive subjects, despite similar BMD. This degradation of bone microarchitecture may help explain the increased skeletal fragility observed in hypertensive patients. PURPOSE: Hypertension is associated with an increased fracture risk. However, evidence on its association with bone mineral density (BMD) is conflicting, and data on bone microarchitectural quality are scarce. The in vivo effects of anti-hypertensive medications on bone quality are poorly explored. The primary aim of this study was to evaluate whether bone microarchitecture, non-invasively assessed by trabecular bone score (TBS), is altered in hypertensive patients. The association between anti-hypertensive medications and TBS was also evaluated as a secondary endpoint.
methodsWe extracted individual data of 7053 subjects included in the 2005-2008 cycles of the National Health and Nutrition Examination Survey (NHANES), in which lumbar spine dual-energy X-ray absorptiometry (DXA) scans were acquired. TBS values were calculated from DXA images using dedicated software. The association between hypertension, anti-hypertensive medications, and bone outcomes was assessed by regression analyses, adjusted for relevant confounders.
resultsHypertension was independently associated with lower TBS values (β = -0.010; 95%CI, [-0.016, -0.003]; p = 0.008); on the contrary, no association was observed between hypertension and BMD at any site (lumbar spine: p = 0.362; total hip: p = 0.481; femoral neck: p = 0.298). No class of anti-hypertensive medications was significantly associated with TBS. Thiazide diuretics and angiotensin receptor blockers were associated with higher BMD values, whereas loop diuretics and non-dihydropyridine calcium channel blockers were associated with lower BMD values.
conclusionsHypertension is associated with degraded bone microarchitecture, while no association is observed with bone mass. No significant relationships between anti-hypertensive medications and TBS were found. Associations between anti-hypertensive medications and BMD were consistent with previous reports.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.